Managers / Q2 2024 · view latest →
Krensavage Asset Management, LLC
CIK 0001609251 · 610 FIFTH AVENUE, SUITE 301, NEW YORK, NY, 10020 · 212-888-1582
Summary
Krensavage Asset Management, LLC reported $218M in U.S.-listed holdings across 13 positions for Q2 2024.
Its largest position, EXEL, represents 17.3% of the portfolio.
Compared with Q1 2024, the fund opened 1 new position and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 78.7% · $172M
- Other · 12.9% · $28M
- ADR · 8.3% · $18M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2024 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| VNDAVANDA PHARMACEUTICALS INC | NEW | +662.2K | 662.2K | +$4M | $4M |
| REGNREGENERON PHARMACEUTICALS | TRIMMED | −4.6K | 7.9K | −$4M | $8M |
| UTHRUNITED THERAPEUTICS CORP | TRIMMED | −38.5K | 118.2K | +$2M | $38M |
| MURAL ONCOLOGY PLC | TRIMMED | −12.9K | 75.1K | −$194,000 | $236,000 |
| ENTAENANTA PHARMACEUTICALS INC | ADDED | +126.8K | 1.25M | −$3M | $16M |
| BNTXBIONTECH SE-ADR | ADDED | +12.3K | 132.3K | −$439,000 | $11M |
| JAZZJAZZ PHARMACEUTICALS PLC | ADDED | +7.9K | 109.1K | −$539,000 | $12M |
| BIIBBIOGEN INC | TRIMMED | −10.3K | 123.8K | −$213,000 | $29M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2024
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | EXELEXELIXIS INChistory → | COM | 17.31% | $38M | 1.68M |
| 2 | UTHRUNITED THERAPEUTICS CORPhistory → | COM | 17.29% | $38M | 118.2K |
| 3 | BIIBBIOGEN INChistory → | COM | 13.18% | $29M | 123.8K |
| 4 | TARO PHARMACEUTICAL INDUS | COM | 12.83% | $28M | 650.1K |
| 5 | CAHCARDINAL HEALTH INChistory → | COM | 9.83% | $21M | 217.7K |
| 6 | ENTAENANTA PHARMACEUTICALS INChistory → | COM | 7.45% | $16M | 1.25M |
| 7 | JAZZJAZZ PHARMACEUTICALS PLChistory → | COM | 5.35% | $12M | 109.1K |
| 8 | BNTXBIONTECH SE-ADRhistory → | COM | 4.88% | $11M | 132.3K |
| 9 | REGNREGENERON PHARMACEUTICALShistory → | COM | 3.79% | $8M | 7.9K |
| 10 | SNYSANOFI-ADRhistory → | COM | 3.43% | $7M | 153.8K |
| 11 | ALKSALKERMES PLChistory → | COM | 2.85% | $6M | 257.6K |
| 12 | VNDAVANDA PHARMACEUTICALS INChistory → | COM | 1.72% | $4M | 662.2K |
| 13 | MURAL ONCOLOGY PLC | COM | 0.11% | $236,000 | 75.1K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $256M | 20 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $283M | 18 | Feb 18, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $235M | 17 | Nov 17, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $189M | 15 | Aug 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $181M | 14 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $169M | 12 | Feb 18, 2025 | RESTATEMENT | changes · EDGAR ↗ |
| Q3 2024 | $178M | 13 | Nov 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $218M | 13 | Aug 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $226M | 12 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $282M | 12 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $272M | 12 | Nov 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $316M | 12 | Aug 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $329M | 12 | May 16, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $324M | 12 | Feb 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $314M | 14 | Nov 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $302M | 14 | Aug 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $290M | 13 | May 17, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $288M | 10 | Feb 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $319M | 13 | Nov 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $295M | 13 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $289M | 12 | May 18, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $342M | 12 | Feb 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $314M | 11 | Dec 8, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2020 | $368M | 11 | Aug 20, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q1 2020 | $311M | 13 | May 18, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $293M | 12 | Feb 18, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $260M | 10 | Nov 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $308M | 10 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $370M | 12 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.